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Abstract
PFRED a software application for the design, analysis, and visualization of antisense oligo-
nucleotides and siRNA is described. The software provides an intuitive user-interface for
scientists to design a library of siRNA or antisense oligonucleotides that target a specific
gene of interest. Moreover, the tool facilitates the incorporation of various design criteria that
have been shown to be important for stability and potency. PFRED has been made available
as an open-source project so the code can be easily modified to address the future needs of
the oligonucleotide research community. A compiled version is available for downloading at
https://github.com/pfred/pfred-gui/releases/tag/v1.0 as a java Jar file. The source code and
the links for downloading the precompiled version can be found at https://github.com/pfred.
Introduction
Over the last three decades small interfering ribonucleic acid (siRNA) and antisense oligonu-
celotides (ASO) have emerged as powerful tools to modulate the expression of genes in vivo
and in vitro. Potential oligonucleotide therapeutics have been discovered and developed with
mixed success [1,2]. For example, Mipomersen, Inotersen, Patisiran and Givlaari have all been
approved for use in recent years. Mipomersen a lipid lowering agent that targets the ApoB
gene [3,4] was eventually approved by the United States Food and Drug Administration
(FDA) in 2013 and later discontinued due to adverse effects [5]. Inotersen (antisense) and Pati-
sirian (first ever siRNA approved by FDA) are both targeting transthyretin (TTR) for the treat-
ment of polyneuropathy caused by hereditary transthyretin-mediated amyloidosis [6,7], while
Givlaari (world’s first-ever approved GalNAc-conjugate RNAi therapeutic) targets aminolevu-
linic acid synthase 1 (ALAS1) for the treatment of acute hepatic porphyria [8]. Furthermore,
the approval of Nusinersen for the treatment of spinal muscular atrophy (SMA) in pediatric
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and adult patients represents a historical achievement for the SMA community and a success
story for the field of nucleic acids based therapeutics [9].
However, the development of oligonucleotide therapeutics remains challenging as they
often have unintended off-target effects and cause non-specific hepatic and renal toxicity [10–
12]. Additionally, it is exceptionally difficult to deliver oligonucleotides to most tissue types
and organs. This can result in the need for tissue specific delivery systems and several siRNA
compounds have advanced into development using this paradigm; these include liposomally
liver targeted ALN-RSV01 which targets RSV through the nucleocapsid “N” gene [13], PF-
4523655 for age related macular degeneration targeting the eye through direct injection [14]
and galNac conjugates [15] such as the late stage ALN-AT3 [16] targeting antithrombin for the
treatment of hemophilia. The recent FDA approval of Patisiran [17] represents a first-of-its-
kind RNA interference (RNAi) therapeutic for the treatment of the polyneuropathy of heredi-
tary transthyretin-mediated (hATTR) amyloidosis in adults and the first ever FDA approval of
a siRNA treatment [7].
Designing antisense oligonucleotides (ASOs) and siRNA can be logistically challenging
given the many competing design criteria that can be incorporated into the selection of tool or
therapeutic sequences. Design considerations may include splice variants, cross-species target-
ing for validation, single nucleotide polymorphisms (SNPs), secondary structure, undesirable
motifs (e.g. toxic, poly-A, or poly-G repeats), complementarity with off-target sequences,
intron/exon boundaries, chemical modification pattern of nucleotides, and predicted activity.
These factors need to be weighed according to the intended use of the oligonucleotide. For
example, compounds designed as in vitro tools only need to be active in a single species,
whereas it is advantageous for therapeutic oligonucleotides to be active in model organisms as
well as patients. A number of computational tools have been developed to address different
aspects of the design process, including OptiRNAi [18], siExplorer [19], DSIR [20], i-Score
[20,21], MysiRNA-Designer [22], siDirect [23,24], siRNA Selection Server [25], siRNArules
[26] and siRNA-Finder [27]. Additionally, major vendors of siRNA reagents such as Dharma-
con (siDESIGN Center) [28], GeneScript (Target Finder) [29] and Thermo Fisher (BLOCK-
iT) [30] have web based design tools available.
In the present paper we describe PFRED (PFizer RNAi Enumeration and Design tool), a
client-server software system designed to assist with the entire oligonucleotide design process,
starting with the specification of a target gene (Ensembl ID) and culminating in the design of
siRNAs or RNase H-dependent antisense oligonucleotides. Sequences are chosen using bioin-
formatics algorithms built upon careful mining of the sequence-activity relationships found in
public datasets as well as internal collections. The tool provides researchers with a user-friendly
interface where the only required input is an accession number for the target gene and it
returns a list of properties that are believed to contribute to the efficacy of an siRNA or ASO.
These properties include human transcripts and cross-species homology, GC content, SNPs,
intron-exon boundary, duplex thermodynamics, efficacy prediction score and off-target
matches. An automated oligonucleotide selection procedure is available to quickly select one
potential set of sequences with an appropriate property profile. The selection protocol can be
customized by the user through changes of the selection cutoffs or the addition of alternate
design parameters and algorithms.
Materials and methods
PFRED is implemented using a client-server software architecture. On the client-side, the
graphical user interface (GUI) was developed in the Java programming language and is
deployed to a user’s desktop through Java Web Start, the user will need to have a recent version
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of the Java development kit setup in their system. Because of the cross-platform support of
Java, PFRED can be run from multiple desktop environments such as Windows, Mac and
Linux. The most CPU-intensive algorithms used in PFRED are implemented as Python and
Perl scripts which are wrapped within a docker container that works as a web service hosted in
an Amazon Web Service (AWS) instance and invoked remotely from the client through a
RESTful API, also developed in Java. Beyond the performance improvements, the client-server
architecture also greatly simplifies the integration of disparate design algorithms that often
rely on heterogeneous third-party libraries or reference datasets. Calls to the server-side algo-
rithms are made through the PFRED java web service which uses the REST API that was devel-
oped using the Glassfish Jersey Java modules. New algorithms can be added to PFRED
following the conventions established for the existing tool.
To facilitate the use of PFRED, users only need to download the latest GUI release and run
it on their own computer; it is also possible for users to build their own private PFRED service
by downloading the PFRED Docker repository in order to create and run the PFRED Service
container following the documentation given at https://github.com/pfred/pfred-docker. This
technique named containerization, facilitates cloud and server agnosticism, because the con-
tainer automatically builds the needed environment for the PFRED back-end to work; users
can also use this local service to test their own alternative algorithms or models, and deploy the
PFRED service in a cloud environment like AWS, Azure, Google cloud, or on a local server. It
is only required for the user to have Docker and Docker-compose setup in the system (see
https://docs.docker.com/compose/). The current client-server architecture consists on an
already built-in Docker Service within a publicly queryable AWS instance managed by Biogen,
which offers a REST API for easy PFRED end-point access to all the back-end services (see
https://github.com/pfred/pfred-rest-service for documentation on how to compile the REST
source code and access the PFRED end-points using a browser). The PFRED GUI takes advan-
tage of the RESTful API in order to access all the needed end-points for ASO and siRNA
design (Fig 1 illustrates the PFRED high-level architecture). The ENSEMBL database is used to
query all genomic information requested by the backend modules. In contrast, the Docker
Volume within AWS is used as both, data warehouse and local storage of the backend mod-
ules. Therefore, the data transferred to the Docker volume varies with the outputs given by the
modules, whereas the ENSEMBL database serves as an external static warehouse (PFRED uses
the latest versioning of ENSEMBL). The PFRED GUI serves as the front end that manages the
calls between modules and the type of data requested by the user for design (Fig 2).
Fig 3 gives an example of the main PFRED interface showing the enumerated antisense
sequences and data annotations related to these compounds. Oligonucleotide sequences and
their properties can be easily visualized and analyzed in the main table. This main PFRED
table provides most of the common spreadsheet functions such as alphanumeric sorting, col-
umn/row resizing, column coloring and conditional coloring. In addition, users can choose
which properties are displayed in the table and customize the display order by drag-and-drop.
To help users sift through large numbers of sequences, the main table supports filtering by
either sequence patterns or property values. For example, a user can search for oligonucleo-
tides that are conserved between human and mouse and have high predicted siRNA efficacy.
Oligonucleotides can also be organized into different groups and then reviewed separately.
Additional functions are also included to help users analyze their data. For example, the math-
ematical formula feature can be used to apply weights to multiple properties and summarize
them into a single score for ranking and selection. The data can be exported as a comma sepa-
rated file (CSV) and then imported into other applications for further analysis.
A key element of PFRED’s functionality is its canonical representation of oligonucleotide
structures. In a separate paper [31] we presented a monomer based notation language to
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represent complex biomolecule structures (the Hierarchical Editing Language for Macromole-
cules or HELM) and a desktop application named PME (Pfizer Macromolecule Editor) for
their drawing and visualization, which has become an industry standard for biopolymer nota-
tions [32]. Fig 4A shows an example of HELM notation for a short antisense gapmer. As poly-
meric biomolecules, antisense oligonucleotides and siRNAs can be represented with HELM
notation and different sequence visualization options can be created for specific purposes.
Included within PFRED are three oligonucleotide representations, shown in Fig 4B–4D. Fig
4B shows an explicit component or monomer view of the oligonucleotide breaking it down
into sugars, bases and linkers. A sequence view is shown in Fig 4C, using a standard notation
with RNA (capital) and DNA (lowercase) but emphasizing “chemical modifications” through
the use of the pink dots. For example, the sequence shown in Fig 4C has a fully phosphor-
othioated backbone which is denoted by the pink dots between the base letters. It also has
three locked nucleic acids (LNAs) at the 3’ and 5’ ends of the compound that are distinguished
by the pink dots above the letters denoting these nucleosides. A final block representation is
shown as Fig 4D. The block representation was created to emphasize patterns of chemical
modifications to a structure. Base modifications are shown as pink dots below the blocks, sug-
ars are colored depending on their structure (e.g. LNA-yellow, 2’OMe-purple, etc.) and back-
bones other than phosphodiesters are represented by pink connectors above the blocks.
The PFRED enumeration workflow is shown in Fig 5. Transcript IDs and sequences of a
target for different ortholog species (human, rat, mouse, dog, chimpanzee and macaque) are
Fig 1. High-level representation of the PFRED client-server architecture based on the AWS and Docker containerization.
https://doi.org/10.1371/journal.pone.0238753.g001
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retrieved from the public ENSEMBL database through the ENSEMBL REST API (please refer
to https://rest.ensembl.org/) given a single transcript or gene ID. Users define a primary tran-
script sequence and their length of choice (k) for all the possible ASO and siRNA k-mers to be
enumerated (Fig 5, steps 1–3). Each enumerated oligonucleotide is then aligned to the other
selected transcripts including splice variants and ortholog transcripts across different species
using the fast memory-efficient short read aligner, Bowtie, against the pre-calculated Bowtie
index covering all transcript sequences [33]. Alignment results are processed by a Python
interface and the number of mismatches to each transcript is reported back to PFRED as
properties of the oligonucleotides. Exon location and SNP information are also retrieved
through the EnsEMBL APIs for each base position and mapped to each oligonucleotide as
properties.
Pre-built bowtie indexes for all species are required for off-target searches. These were built
by creating a Python interface that automatically downloads all transcripts (cDNA) and
unspliced gene sequences for any species in FASTA format using the ENSEMBL REST API
which provides the advantage of always relying on the latest version of the ENSEMBL data-
base. The FASTA files are written with transcript ID and Gene ID included in the sequence
names. These FASTA files are used to build indexes for searching cDNA and gene off-target
matches. The ENSEMBL IDs are used for post-processing the bowtie alignment results to cal-
culate the number of genes that an oligonucleotide aligns to with 0, 1 and 2 mismatches, and
to exclude the intended target from the off-target count. For siRNA, only the cDNA database
is searched for both the guide and passenger strands. In contrast, for antisense design, only the
sense sequences (or antisense sequence in reverse complementary direction) is searched
against both the cDNA and unspliced gene sequence indexes for off-target hits. The number of
cDNA off-target hits is then reported as an oligonucleotide property for 0, 1 and 2 mismatches.
While the off-target search module is not based on any predictive model or experimental data,
it can be used effectively as an annotation tool to help the user prioritizing and filtering
sequences through the PFRED screening funnel.
Fig 2. Data flow diagram of the PFRED backend.
https://doi.org/10.1371/journal.pone.0238753.g002
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Due to the cost of synthesizing and testing siRNAs and ASOs, rational design represents a
critical step in any oligonucleotide experiment. A priori prediction of a compound’s function
is a key component of RNAi and ASO applications to obtain effective silencing of the desired
Fig 3. PFRED user interface. The main “Oligo Table” stores all the data generated through the oligo enumeration workflow (oligo sequences with
their properties) and provides access to common spreadsheet functions. It is possible to assign selected oligo sequences to specific groups which can
be shown and accessed under “Groups” on the right-side panel. More detailed information about the oligo sequence notation and the primary
mRNA transcript can be visualized at the bottom of the user interface by enabling the “Oligo Detail” and “Target Transcript” panels.
https://doi.org/10.1371/journal.pone.0238753.g003
Fig 4. PFRED RNAi notation. Alternative representations of a short antisense gapmer sequence using the HELM notation (A) and different
sequence visualization options (B-D).
https://doi.org/10.1371/journal.pone.0238753.g004
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gene. Early models were based on empirical rules for designing functional siRNA, obtained
from the experimental results of ASO and RNAi screening campaigns. For RNAi sequence
design, Tuschl [34,35] first and later Reynolds [36] reported a series of guidelines for the
implementation of a “point-based” scoring scheme where the presence or absence of key fea-
tures in an siRNA duplex will lead to an increase or decrease of the final functional score. Sev-
eral other algorithms have emerged since then [19,20,37–42] based on more sophisticated
scoring schemes which use sequence descriptors and supervised machine learning techniques
Fig 5. Oligo enumeration and annotation workflow. The process of designing an ASO or siRNA in PFRED starts with the Advanced Oligo
Enumerator (1) by providing the Ensembl ID of a target of interest and the list of ortholog species to design against. The Retrieve Ortholog
Sequence button (2) uses the Ensembl REST API to communicate with the public Ensembl database to retrieve all the sequence information related
to the gene of interest (splice variants and ortholog transcripts). At this point the user has the option to choose the Design type (siRNA design or
AntiSense design) as well as additional oligo annotations (Off-target and Efficacy predictions) before triggering the Enumerate & Annotate button
(3). Once all the descriptors have been calculated for each potential ASO or siRNA the design workflow becomes a process of selection (4).
https://doi.org/10.1371/journal.pone.0238753.g005
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to select siRNAs capable of inducing effective gene silencing in cell lines. In PFRED, an algo-
rithm for predicting siRNA functionality has been implemented by using diverse sets of oligo-
nucleotide descriptors combined with a support vector machine (SVM) algorithm. Details of
the sequence descriptors and algorithm implementation were previously described elsewhere
[43]. Models of ASO activity have also improved but can be highly dependent on the length of
the ASO as well as its chemical modification. Most published models use either sequence motif
based filters [44] or computational approaches including secondary structure prediction [45–
47], thermodynamics [48,49], machine learning [50–52] and molecular dynamics simulation
[53], but all have reported only limited success. Here we integrated both the thermodynamics
parameters calculated using Oligowalk [54] and the sequence motifs reported in Matveeva
[44]. Using these parameters, a scoring scheme was derived that penalized motifs correlated
with toxicity or promiscuity, strong inter- and intra-molecular binding energy as well as weak
binders to the RNA target [10,43]. The model was derived and tested using data from AOBase
[55] including more than 500 ASOs against 46 targets. The thermodynamic calculations were
based on unmodified DNA antisense oligonucleotides and therefore of limited relevance to
modifications that significantly increase the melting temperature (Tm) of DNA/RNA duplex
such as LNA.
Once all the descriptors have been calculated for each potential ASO or siRNA the design
workflow becomes a process of selection. An example of the PFRED selection interface for
siRNA design is shown in Fig 5, step 4. Oligonucleotide selections are made by first filtering
out those compounds which align with: 1) known human SNPs, 2) sequence motifs associated
with non-specific binding (such as polyG, polyT) and 3) low complexity sequences that have a
high number of perfect off-target matches. An additional filter for ortholog transcript matches
can be added depending on the experimental design requirement. Also, if predicted activities
are available, they may be included as a selection criterion (models may depend on a specific
oligonucleotide length or modification type). Other oligonucleotide properties such as number
of off-target matches and diversity of location of each oligonucleotide along the gene sequence
can be used to finalize the selection of desired compounds for a given experiment. The final
selected compounds can then be exported in text format in preparation for synthesis or further
analysis outside of the tool.
Conclusions
We present here an informatics platform for the design of antisense and siRNA oligonucleo-
tides. The system includes a basic set of design algorithms but is extensible such that experi-
enced developers can add novel or proprietary descriptors. Workflows are included which
walk researchers through the process of identifying a target sequence and choosing the design
criteria to be applied in selection of candidate molecules. A series of oligonucleotide visualiza-
tion and plotting algorithms are included along with spreadsheet functions allowing data
import/export, formulas, and conditional formatting. Links to the source code and hosted ver-
sions can be found at https://github.com/pfred.
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